Latest News-Innovent Biologics,Inc Mediaroom_Page

Innovent and Lilly Expand Strategic Partnership in Oncology

SAN FRANCISCO and INDIANAPOLIS and SUZHOU, China, March 28, 2022 /PRNewswire/ -- Innovent Biologics...

2022-03-28 08:00 4868

Innovent Biologics and AnHeart Therapeutics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, March 1, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2022-03-01 08:48 2877

Innovent Announces First Patient Dosed with CD73 Antibody in Phase 1a/1b Clinical Trial for Advanced Solid Tumor

SAN FRANCISCO and SUZHOU, China, Feb. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2022-02-24 08:00 3317

Innovent Announces First Patient Dosing of Universal "Modular" CAR-T Cell product IBI345

SAN FRANCISCO and SUZHOU, China, Feb. 21, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2022-02-21 08:00 3131

Innovent Announces Two Registration Studies of IBI306 (anti-PCSK-9 antibody) Met Primary Endpoint

SAN FRANCISCO and SUZHOU, China, Feb. 17, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2022-02-17 08:00 4011

U.S. FDA Grants Orphan Drug Designation to BCMA CAR-T Cell Therapy Co-Developed by Innovent and IASO Bio

SAN FRANCISCO and SUZHOU, China, Feb. 14, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2022-02-14 08:00 3895

FDA Advisory Committee Votes to Recommend Additional Data for Sintilimab Submission

SAN FRANCISCO, and SUZHOU, China, Feb. 11, 2022 /PRNewswire/ -- The U.S. Food and Drug Administrati...

2022-02-11 10:44 3567

Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma With A FGFR2 Fusion Or Rearrangement That Have Progressed After At Least One Prior Line Of Systemic Therapy

SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2022-01-24 15:22 4095

Innovent and Eli Lilly and Company Announced Final Clinical Results and Biomarker Analysis of Phase Ib Study of TYVYT® (Sintilimab Injection) Plus Bevacizumab Biosimilar Injection for Advanced Hepatocellular Carcinoma at ASCO GI Annual Meeting 2022

SAN FRANCISCO and SUZHOU, China, Jan. 22, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2022-01-22 08:00 8222

Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct

SEATTLE, SAN FRANCISCO, SAN JOSE, Calif., NANJING, China, SUZHOU, China and SHANGHAI, Jan. 11, 2022...

2022-01-11 05:30 3567

Innovent Announces NMPA of China Acceptance of a Supplemental New Drug Application for TYVYT® (Sintilimab Injection plus Bevacizumab Biosimilar Injection and Chemotherapy in Patients with EGFR-mutated Non-squamous Non-small Cell Lung Cancer who Progressed after EGFR-TKI Therapy

SAN FRANCISCO and SUZHOU, China, Dec. 24, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-12-24 16:51 10106

Innovent Announces Pivotal Phase 2 Results for Parsaclisib (PI3Kδ inhibitor) Presented at ASH 2021 Show Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma

SAN FRANCISCO and SUZHOU, China, Dec. 14, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-12-14 08:00 2893

Innovent and IASO Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting

SAN FRANCISCO, U.S. and SUZHOU, China, Dec. 13, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Inn...

2021-12-13 08:00 2998

Innovent Releases Results of a Phase 1 Clinical Study of IBI362, a Dual Glucagon-like Peptide-1 and Glucagon Receptor Agonist in Chinese Patients with Type 2 Diabetes at the International Diabetes Federation Congress 2021

SAN FRANCISCO and SUZHOU, China, Dec. 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2021-12-07 08:00 3264

Innovent and Lilly Announce Successful Expansion of Sintilimab in China National Reimbursement Drug List to Include Three Additional First-Line Indications

SAN FRANCISCO, INDIANAPOLIS, and SUZHOU, China, Dec. 3, 2021 /PRNewswire/ -- Innovent Biologics, In...

2021-12-03 12:37 3870

Innovent Biologics and Ascentage Pharma Announce the China NMPA Approval for China's First Third-Generation BCR-ABL Inhibitor Olverembatinib for the Treatment of Chronic Myeloid Leukemia

SUZHOU, China, SAN FRANCISCO and ROCKVILLE, Md., Dec. 1, 2021 /PRNewswire/ -- Innovent Biologics, I...

2021-12-01 08:00 2785

Innovent Releases the ORIENT-31 Phase 3 Study First Interim Analysis Results of Sintilimab plus BYVASDA (bevacizumab biosimilar injection) and Chemotherapy in Patients with EGFR-mutated Nonsquamous Non-small Cell Lung Cancer who Progressed After EGFR-TKI Therapy at ESMO Virtual Plenary 2021

SAN FRANCISCO and SUZHOU, China, Nov. 22, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-11-22 08:16 2985

Innovent Announces Inclusion of the Company's Stock (01801.HK) in the Hang Seng China Enterprises Index

SAN FRANCISCO and SUZHOU, China, Nov. 22, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-11-22 08:00 3499

Innovent Announces the Results of the Phase Ib Clinical Trial of IBI302, a First-in-class Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2021 American Academy of Ophthalmology

SAN FRANCISCO and SUZHOU, China, Nov. 15, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-11-15 08:00 2617

Innovent Publishes the Preclinical Results of IBI319 (Anti PD-1/CD137 Bispecific Antibody) in Nature Communications

SAN FRANCISCO and SUZHOU, China, Nov. 8, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-11-08 08:00 2993